June 13, 2016
Cambridge, MA

Multiple Charities Join Solid to Defeat Duchenne muscular dystrophy

Solid is proud to announce that three leading charities from around the world, Duchenne Now, Save Our Sons and Fight DMD, have joined our fight to solve Duchenne muscular dystrophy (DMD) and improve the lives of patients.  The generous grants provided by these organizations will directly fund our research programs to find new breakthroughs in DMD treatment. 

The grants include:

Duchenne Now: The U.K.-based organization founded by Tony Levene, Vici Richardson and Paul Fitzpatrick has committed a one-time grant of $150,000 to fund our Disease Modifying Therapy programs targeted at managing the symptoms associated with disease progression.

Fight DMD: Founded by Terry Marlin in Tennessee USA, the organization has committed $100,000 dollars over two years to fund efforts within our Solid GT program to identify next generation technologies that may restore dystrophin protein expression in the body.

Save Our Sons: The Australian organization founded by Elie Eid has committed $400,000 Australian Dollars over two years to fund different efforts within our Disease Modifying Therapy and Solid GT programs, including the development of potential symptomatic therapies, certain aspects of our AAV-associated micro-dystrophin gene therapy program and our ongoing efforts to uncover new technologies that may restore dystrophin expression.

“I want to give special thanks to each of the children for which these charities were formed – Emilio, Joey, Josh, Zak, Raul, Jonah and Emory,” said Annie Ganot, head of Patient Advocacy at Solid Biosciences.  “It is you and your families who inspire us every day in our work to develop treatments for all boys and young men with Duchenne muscular dystrophy.”

This is the first time that Duchenne Now, Save Our Sons and Fight DMD have contributed grants to Solid Biosciences.  As part of our commitment to partnership and transparent communication, Solid will provide each organization with regular updates to show our work and progress.

If you are a charity and would like to partner with Solid on ongoing projects,

Click Here

Related news


Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET


- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial

Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial


- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -


Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.


Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.


Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.


More information about Solid?

Please subscribe to receive our latest news